On November 17, 2026, the U.S. Food and Drug Administration proposed withdrawing approval for Salerno Pharmaceuticals' FloLipid, a liquid simvastatin oral suspension approved in 2016 for high cholesterol patients with swallowing difficulties. The FDA cited Salerno's repeated failure to submit required annual reports and lack of response to agency requests. Salerno will be offered an opportunity for a hearing before withdrawal.
FDA action on FloLipid approval
- ▪On November 17, 2026, the U.S. Food and Drug Administration drug evaluation department proposed withdrawing approval for Salerno Pharmaceuticals' FloLipid because Salerno repeatedly failed to submit required annual reports and respond to agency requests
- ▪The U.S. Food and Drug Administration is offering Salerno Pharmaceuticals an opportunity for a hearing to argue why approval for FloLipid should not be withdrawn
- ▪Holders of approved human drug applications are required by the U.S. Food and Drug Administration to submit annual reports containing updated labeling, chemistry, manufacturing, and control details
FloLipid history and manufacturing
- ▪FloLipid, approved in 2016 as a simvastatin oral suspension, was developed as a liquid LDL cholesterol-lowering medication for patients who experience difficulty swallowing pills
- ▪Salerno Pharmaceuticals' simvastatin oral suspension FloLipid was previously manufactured for Rosemont Pharmaceuticals, a Perrigo company
FloLipid dosing and myopathy risks
- ▪In 2020, the product label for FloLipid simvastatin oral suspension was updated to include a warning regarding rare reports of statin-associated immune-mediated necrotizing myopathy
- ▪The recommended starting dose for FloLipid simvastatin oral suspension is 10 mg or 20 mg administered once daily in the evening on an empty stomach
- ▪Patients receiving an 80-mg dose of FloLipid simvastatin oral suspension carry an increased risk of developing myopathy, including rhabdomyolysis
Story comments
Loading comments…